Of the 11 identified DEGs, ACTL6A expression was found to play important roles in ovarian cancer progression and to be closely correlated with adverse prognosis for overall survival (OS) and progression-free survival (PFS) in ovarian cancer patients. This evidence concerns the gene ACTL6A and ovarian cancer.